(CRSP) CRISPR Therapeutics AG Business Model Canvas Research

CRISPR Therapeutics AG’s Nkarta, Inc. cell-therapy collaboration supports engineered immune-cell work and broadens its reach in allogeneic cell therapy beyond CAR-T. It also helps spread R&D cost and risk across partners, which matters in a field where each new cell-therapy program can take years and significant capital.

• Supports engineered immune-cell therapy development
• Expands beyond CAR-T into allogeneic cell therapy
• Shares R&D burden and program risk

Capsida Biotherapeutics gives CRISPR Therapeutics AG a delivery edge for in vivo gene editing, adding vector design and tissue targeting for liver, muscle, lung, and central nervous system programs. The deal matters because delivery is still the main bottleneck in gene editing, and Capsida’s platform helps CRISPR Therapeutics AG push beyond ex vivo work into harder-to-reach organs.

• Supports in vivo editing
• Adds tissue targeting
• Helps hard-to-reach organs

CRISPR Therapeutics AG is pushing in vivo gene-editing programs across 4 target areas: liver, lung, muscle, and CNS. The work centers on vector engineering, biodistribution, and target validation, which are the core steps needed to edit cells directly inside the body and move the platform beyond ex vivo therapy.

• 4 disease areas in direct-body editing
• Vector design drives tissue targeting
• Biodistribution work checks where edits go
• Target validation reduces clinical risk

CRISPR Therapeutics AG runs clinical trials, CMC work, and FDA/EMA filings to move cell and gene therapies from lab to market. In FY2025, its approved therapy CASGEVY already showed why this matters: every step needs tight safety tracking, batch control, and long regulatory review.

• Runs trials and tracks safety
• Builds GMP manufacturing
• Manages global submissions

CRISPR Therapeutics AG depends on specialized scientific talent in gene editing, cell therapy, translational science, and regulatory work. This human capital is core to moving complex programs from lab to clinic, and the company’s 2025 pipeline still spans multiple development-stage programs plus one approved medicine, CASGEVY.

• Expert teams drive technical risk
• Regulatory skill speeds approvals
• Human capital is a core asset

CRISPR Therapeutics AG’s strategic partner network with Vertex, Bayer, ViaCyte, Nkarta, and Capsida extends reach into gene editing, cell therapy, and in vivo delivery. Vertex’s partnership already led to CASGEVY, the first approved CRISPR therapy, and CRISPR Therapeutics AG reported $1.9 billion in cash, cash equivalents, and marketable securities at year-end 2024, helping fund shared risk.

• Access to complementary science
• Shared development and trial risk
• Broader commercialization pathways
• Better delivery and platform know-how

CRISPR Therapeutics AG is building donor-sourced, off-the-shelf CAR-T therapies for cancer, aiming to cut the 2-4 week wait tied to bespoke autologous manufacturing. That matters most in fast-moving blood cancers, where speed can affect access and outcomes, and scalable batch production can lower unit costs as volume grows.

• Donor-sourced, ready-to-use CAR-T
• Faster dosing than bespoke therapy
• Better fit for aggressive malignancies
• More scalable manufacturing model

CRISPR Therapeutics AG’s value lies in a broad pipeline across 4 core areas: blood disorders, oncology, regenerative medicine, and rare disease, plus in vivo work for liver, lung, muscle, and CNS targets. That spread lowers single-asset risk and gives the Company more shots at value creation, with Casgevy as the first approved gene-edited therapy.

• 4 therapeutic areas
• 4 in vivo target organs
• Lower program concentration risk
• More flexible capital allocation

CRISPR Therapeutics AG uses partner-managed commercialization for advanced programs like CASGEVY, with Vertex handling launch and market access while CRISPR Therapeutics AG keeps a shared role in development and post-approval support. This model scales a small base: CRISPR Therapeutics AG ended 2025 with about $1.5 billion in cash, cash equivalents, and marketable securities, so partner reach helps extend runway and reduce launch burden.

• Shared customer interface
• Lower launch cost load
• Scales lean resources

Scientific and medical education is central to CRISPR Therapeutics AG because Casgevy is a one-time ex vivo gene-editing therapy that only works if clinicians, payers, and treatment centers understand the mechanism, eligibility, and outcome data. This matters in a market where the therapy is still scaling, and CRISPR Therapeutics reported $33.6 million in collaboration revenue in Q1 2025.

• Train clinicians on patient selection.
• Explain outcomes and safety data.
• Build payer confidence for reimbursement.
• Support center readiness and adoption.

Vertex and other partners give CRISPR Therapeutics AG direct access to hospitals, payers, and regulators for marketed or near-market assets like CASGEVY, which was approved in multiple major markets through 2025. That setup lets CRISPR Therapeutics AG avoid building a large internal sales force and shifts launch execution to partners with existing commercial reach.

• Best for near-market launches

• Uses Vertex's commercial network

• Limits sales-force spend

CRISPR Therapeutics AG uses peer-reviewed journals, congresses, and digital medical education to explain clinical data and safety, which matters in a field with only 1 approved gene-edited therapy so far. These channels help build trust with clinicians and payers, where adoption depends on clear evidence, not marketing.

• Peer-reviewed data supports credibility.
• Congress talks reach key prescribers.
• Digital education scales medical reach.

This channel mix is vital in advanced biotechnology because launch decisions hinge on efficacy, durability, and managed access, not just brand awareness. It also helps position CRISPR Therapeutics AG for future readouts and reimbursement talks.

Type 1 diabetes affects about 1.3 million Americans and is a lifelong disease with no cure, so VCTX210 targets a large, chronic need. The segment is still development-stage, but success would move CRISPR Therapeutics AG beyond oncology and hematology into a much bigger market.

• Large, unmet chronic need
• Still in development
• Could broaden CRISPR Therapeutics AG

Healthcare systems and payers are CRISPR Therapeutics AG’s gatekeepers: they fund, authorize, and reimburse high-cost therapies like Casgevy, which has a U.S. list price of about $2.2 million per patient. Their coverage decisions shape real access, so this segment is indirect but critical to revenue.

• Fund high-cost one-time therapies
• Approve access and reimbursement
• Set adoption speed and scale

In 2025, CRISPR Therapeutics AG had to keep pharmacovigilance, quality documentation, and compliance systems running across its cell-therapy programs, especially after Casgevy approvals. These costs rise as programs move toward approval because regulatory filings, inspections, and safety tracking need dedicated teams in each market.

• Ongoing safety monitoring stays fixed.
• Filing and inspection costs rise near approval.
• More markets mean more compliance work.

General, IP, and partnership costs at CRISPR Therapeutics AG are a steady drag on the model: corporate overhead, patent upkeep, alliance management, and deal-linked legal work all rise as the platform expands. These costs support a strategy built on multiple collaborations, milestone payments, and broad IP protection, so they stay material even when program spend shifts.

• Corporate overhead stays recurring.
• Patent fees protect core CRISPR IP.
• Alliance costs scale with partners.
• Milestones and legal fees recur.

If CRISPR Therapeutics AG pipeline assets win approval, the company can earn direct sales or profit-share revenue, mainly in hematology, oncology, and regenerative medicine. This is the biggest long-term upside stream; Casgevy already has 2 approved indications, showing the model can turn pipeline into commercial cash.

• Direct product sales or profit-share
• Hematology, oncology, regenerative medicine
• Long-term upside, not near-term core

CRISPR Therapeutics AG can turn its CRISPR platform into non-dilutive cash through licensing and option deals, not just one drug. In FY2025, collaboration revenue still mattered more than product sales, which shows how a broad-tech model can monetize know-how across multiple partners and programs.

• Non-dilutive income from partner deals
• Monetizes IP beyond one product
• Fits a multi-program platform model